Stempeucel®, a cell therapy for the treatment of Critical Limb Ischemia (CLI), has been approved for commercial use in India by the Drug Controller General.
List view / Grid view
Drug Controller General of India (DCGI)
Filter the results
Regulatory bodies in India are tracking the cost of remdesivir and favipiravir amid the COVID-19 pandemic but should consider price caps, a report has suggested.
The Drug Controller General of India (DCGI) approved remdesivir lyophilised powder for emergency use in patients hospitalised with severe COVID-19.